Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies

Volume: 2, Issue: 1, Pages: e186875 - e186875
Published: Jan 4, 2019
Abstract

Importance

High costs and risks of research and development (R&D) have been used to justify the high prices of cancer drugs. However, what the return on R&D investment is, and by extension what a justifiable price might be, is unclear.

Objective

To compare incomes from the sales of cancer drugs with the estimated R&D costs.

Design, Setting, and Participants

This observational study used global...
Paper Details
Title
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
Published Date
Jan 4, 2019
Volume
2
Issue
1
Pages
e186875 - e186875
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.